stockrowKiora Pharmaceuticals, Inc.
KPRX Healthcare Biotechnology
Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million.
- EPS
- +37.0%
- Free cash flow
- +50.1%
Quarter to June 2026, against a year earlier
Follow KPRX
Alert me
Kiora Pharmaceuticals, Inc. (KPRX) EV/Sales
As of 6 November 2026, Kiora Pharmaceuticals, Inc. (KPRX) trades at a EV/Sales of −0.4×. Over the past ten years it has ranged from −4.3× (March 2018) to 74.9× (June 2022); the current reading is higher than 24% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | −0.7× | — |
| FY2020 | 6.7× | 3.96% |
| FY2019 | 6.4× | 29.90% |
| FY2018 | 5.0× | (64.43%) |
| FY2017 | 14.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2024 | −0.5× | — |
| Mar 2024 | −0.8× | — |
| Dec 2020 | 6.7× | 219.55% |
| Mar 2019 | 2.1× | (20.77%) |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| APRE Aprea Therapeutics, Inc. compare | −34.8× |
| IMRN IMMURON compare | −3.5× |
| KPRX Kiora Pharmaceuticals, Inc. | −0.4× |
| ENVB Enveric Biosciences, Inc. compare | −0.1× |
| MTVA MetaVia Inc. compare | n/m |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| SYBX Synlogic, Inc. compare | 0.1× |
| ENSC Ensysce Biosciences, Inc. compare | 1.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)